Medicine and Dentistry
Therapeutic Procedure
100%
Randomized Controlled Trial
95%
Patient
56%
Combination Therapy
36%
Placebo
30%
Aflibercept
30%
Arm
29%
Cost-Effectiveness Analysis
28%
Ranibizumab
23%
Analysis
22%
Health
22%
Amaurosis
22%
Inpatient
22%
Adult
21%
Controlled Clinical Trial
19%
Clinical Trial
19%
Bevacizumab
19%
Diabetic Macular Edema
17%
Kidney Graft
17%
Dark Adaptation
17%
Immunoglobulin
17%
Macular Edema
17%
Central Retinal Vein Occlusion
17%
Disease
16%
Steroid
15%
Enalapril Maleate
15%
Health Care Cost
14%
Screening
14%
Follow up
12%
Injury
12%
Atrial Fibrillation
11%
Surgical Ablation
11%
Opiate Agonist
11%
Child
11%
Persistent Atrial Fibrillation
11%
Cognitive Behavioral Therapy
11%
Catheter Ablation
11%
Chronic Graft Rejection
11%
Eye Injury
11%
Proliferative Diabetic Retinopathy
11%
Prematurity
11%
Nurse
11%
COVID-19
11%
Amyotrophic Lateral Sclerosis
11%
HLA Antibody
11%
Association
11%
Quality of Life
11%
Antibody
11%
Best Corrected Visual Acuity
10%
Injection
10%
Nursing and Health Professions
Patient
31%
Nurse
29%
Aflibercept
29%
Placebo
19%
Diabetic Macular Edema
17%
Dermatitis
17%
Central Retina Vein Occlusion
17%
Ranibizumab
17%
Macular Edema
17%
Bevacizumab
17%
Cost Effectiveness Analysis
16%
Standard
14%
Diseases
13%
Socialized Medicine
12%
Mask
12%
Amyotrophic Lateral Sclerosis
11%
Health Status
11%
Intellectual Impairment
11%
Epilepsy
11%
Proliferative Diabetic Retinopathy
11%
Follow up
11%
Adult
11%
Clinical Effectiveness
11%
Best Corrected Visual Acuity
10%
Combination Therapy
10%
Intention to Treat Analysis
9%
Prevention
8%
Laser Coagulation
8%
Control
8%
Depression
7%
Evaluation Study
7%
Confidence Interval
6%
Inpatient
6%
Analysis
6%
Intensive Care Unit
6%
Opiate
5%
Hospital Discharge
5%
Immunoglobulin
5%
Frailty
5%
Cognitive Behavioral Therapy
5%
Enalapril Maleate
5%
Low Drug Dose
5%
Naltrexone
5%
Cohort Analysis
5%
Alzheimer Disease
5%
Health Service
5%
Injection
5%
Prevalence
5%
Adverse Event
5%